Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson’s disease was written by Lee, Byoung Dae;Shin, Joo-Ho;Van Kampen, Jackalina;Petrucelli, Leonard;West, Andrew B.;Ko, Han Seok;Lee, Yun-Il;Maguire-Zeiss, Kathleen A.;Bowers, William J.;Federoff, Howard J.;Dawson, Valina L.;Dawson, Ted M.. And the article was included in Nature Medicine (New York, NY, United States) in 2010.Electric Literature of C11H13IN4O4 The following contents are mentioned in the article:
Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson’s disease. Here we identify inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of Parkinson’s disease. This study involved multiple reactions and reactants, such as (2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4Electric Literature of C11H13IN4O4).
(2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4) belongs to tetrahydrofuran derivatives. THF (Tetrahydrofuran) is water-miscible and has a low viscosity making it a highly versatile solvent used in a variety of industries. It is more basic than diethyl ether and forms stronger complexes with Li+, Mg2+, and boranes. It is a popular solvent for hydroboration reactions and for organometallic compounds such as organolithium and Grignard reagents.Electric Literature of C11H13IN4O4
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem